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Summary
Background This open-label, first-in-human, phase 1 study evaluated AMG 232, an oral selective MDM2 inhibitor in patients
with TP53 wild-type (P53WT), advanced solid tumors or multiple myeloma (MM). Methods In the dose escalation (n = 39),
patients with P53WT refractory solid tumors enrolled to receive once-daily AMG 232 (15, 30, 60, 120, 240, 480, and 960mg) for
seven days every 3 weeks (Q3W). In the dose expansion (n = 68), patients with MDM2-amplified (well-differentiated and de-
differentiated liposarcomas [WDLPS and DDLPS], glioblastoma multiforme [GBM], or other solid tumors [OST]), MDM2-
overexpressing ER+ breast cancer (BC), or MM received AMG 232 at the maximum tolerated dose (MTD). Safety, pharmaco-
kinetics, pharmacodynamics, and efficacy were assessed. Results AMG 232 had acceptable safety up to up to 240 mg. Three
patients had dose-limiting toxicities of thrombocytopenia (n = 2) and neutropenia (n = 1). Due to these and other delayed
cytopenias, AMG 232 240 mg Q3W was determined as the highest tolerable dose assessed in the dose expansion. Adverse
events were typically mild/moderate and included diarrhea, nausea, vomiting, fatigue, decreased appetite, and anemia. AMG 232
plasma concentrations increased dose proportionally. Increases in serum macrophage inhibitor cytokine-1 from baseline were
generally dose dependent, indicating p53 pathway activation. Per local review, there were no responses. Stable disease (durability
in months) was observed in patients withWDLPS (3.9), OST (3.3), DDLPS (2.0), GBM (1.8), and BC (1.4–2.0).Conclusions In
patients with P53WT advanced solid tumors or MM, AMG 232 showed acceptable safety and dose-proportional pharmacoki-
netics, and stable disease was observed.
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Introduction
The tumor suppressor p53 is a key regulator of cell
cycle progression and apoptosis [1, 2]. Mouse double
minute 2 homolog (MDM2) inhibits p53 activity by
acting as an E3 ubiquitin ligase to promote its degrada-
tion, by binding and blocking the p53 transcriptional
activation domain, and by exporting p53 from the nu-
cleus to the cytoplasm [3, 4]. Among TP53 wild-type
(P53WT) solid tumors, MDM2 amplification has been
demonstrated in well-differentiated and de-differentiated
liposarcomas (WDLPS and DDLPS, respectively) and in
glioblastoma multiforme (GBM) [5, 6]. Overexpression
of MDM2 protein has been shown in WDLPS and
DDLPS, estrogen receptor positive (ER+) breast cancer,
and multiple myeloma [7–11]. MDM2 amplification and
MDM2 overexpression, which result in p53 inactivation
and decreased apoptosis, have been associated with poor
outcomes [12–14].
Although many tumors harbor non-targetable muta-
tions in TP53, MDM2 has become an attractive thera-
peutic target in the treatment of TP53 wild-type
(P53WT) cancers. Several MDM2 inhibitors are in clin-
ical investigation as monotherapy or combined with oth-
er therapies for the treatment of P53WT hematologic
malignancies and solid tumors [15–18]. In clinical stud-
ies of MDM2 inhibitors, increases in circulating macro-
phage inhibitor cytokine-1 (MIC-1) has been used as a
pharmacodynamic marker of p53 activation [19–21].
AMG 232 is an investigational oral, selective MDM2
inhibitor that restores p53 tumor suppression by
blocking the MDM2-p53 interaction with picomolar af-
finity [22]. In tumor xenograft models, treatment with
AMG 232 resulted in tumor growth inhibition and
caused regression of MDM2-amplified tumors through
the induction of growth arrest and apoptosis [23]. The
primary objectives of this open-label, first-in-human,
phase 1 study were to assess the safety and tolerability,
pharmacokinetics, maximum tolerated dose (MTD),
pharmacodynamics, and efficacy of AMG 232 in pa-
tients with P53WT solid tumors or multiple myeloma.
Methods
Patients
Patients aged ≥18 years with pathologically-documented,
P53WT (per next-generation sequencing) treatment-
refractory solid tumors measurable per Response
Evaluation Criteria in Solid Tumors (RECIST) version
1.1 or Macdonald criteria for glioblastoma multiforme
(GBM), or progressive multiple myeloma measurable
per International Myeloma Working Group (IMWG) re-
sponse criteria were eligible. Additional eligibility
criteria were Eastern Cooperative Oncology Group
(ECOG) performance status ≤2; life expectancy
>3 months; adequate hematologic (ANC ≥1.5 × 109/L
for solid tumors or ≥ 1.0 × 109/L for multiple myeloma;
platelet count ≥100 × 109/L for solid tumors or ≥ 75 ×
109/L for multiple myeloma; hemoglobin >9 g/dL), re-
nal (estimated glomerular filtration rate ≥ 45 mL/min/
1.73 m2), hepatic (AST and AST <2.5 × ULN; ALP
<2.0 × ULN; total bilirubin <1.5 × ULN), and coagula-
tion (prothrombin time or partial thromboplastin time <
1.5 × ULN) functions. In the dose expansion, five tumor
t y p e s w e r e d e f i n e d : w e l l - d i f f e r e n t i a t e d o r
dedifferentiated liposarcoma; relapsed GBM with
MDM2 amplification; estrogen receptor positive (ER+)
breast cancer refractory to hormonal treatments; relapsed
multiple myeloma progressive after ≥1 prior treatment;
other advanced solid tumors with MDM2 amplification.
Key exclusion criteria included active or untreated brain
metastases; unresolved toxicity from prior anticancer
therapy, excluding alopecia; antitumor therapy or major
surgery within 28 days of starting study treatment; in-
vestigational device or drug within 30 days or 5 half-
lives of starting study treatment; liposarcomas with >3
prior approved therapies; multiple myeloma with del
(17p) or IgM subtype, non-secretory or hyposecretory
disease, lack of ≥25% reduction in M-protein for
≥6 weeks with prior therapy, corticosteroid therapy
within 3 weeks of study, POEMS syndrome, or plasma
cell leukemia or lymphoplasmacytic lymphoma.
Institutional review board approval was obtained for
all study procedures. All patients provided informed
consent before enrollment.
Study design and treatment
This open-label phase 1 study was conducted at 16 cen-
ters (ClinicalTrials.gov, NCT01723020). TP53 mutation
status was confirmed by central laboratory assessment.
The study was planned with two parts: a 3-part dose
escalation (Part 1) and a dose expansion (Part 2). In
the dose escalation, multiple-patient cohorts were
planned to enroll sequentially (Part 1A) or in parallel
(Parts 1B and 1C; 3 + 3 design) and to receive AMG
232 once daily (QD) for 3 days (Part 1B) or 7 days
(Part 1C) every 3 weeks (Q3W) at prespecified doses of
15, 30, 60, 120, 240, 480, and 960 mg. Intermediate
doses were allowed when deemed appropriate. The dose
e x p a n s i o n w a s p l a n n e d f o r p a t i e n t s w i t h
MDM2-amplified tumors (group 1; liposarcomas, GBM,
and o the r so l id tumors ) , po t en t i a l l y MDM2-
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overexpressing tumors (group 2; ER+ metastatic breast
cancer), or multiple myeloma (group 3).
Each patient was monitored for 21 days for the oc-
currence of dose-limiting toxicities (DLTs), defined as
febrile neutropenia, neutropenic infection, grade 4 neu-
tropenia lasting >7 days, grade ≥ 3 thrombocytopenia
lasting >7 days (solid tumors only), grade 3 thrombocy-
topenia with grade ≥ 2 bleeding (solid tumors only),
grade 3 or 4 thrombocytopenia with grade > 1 bleeding
(multiple myeloma only), grade 4 thrombocytopenia
(solid tumors only), or grade 4 thrombocytopenia lasting
>14 days (multiple myeloma only), or as grade ≥ 3 nau-
sea, vomiting, or diarrhea after support; grade 3 fatigue
lasting >7 days; any other grade ≥ 3 adverse event (AE);
grade ≥ 3 kidney injury (multiple myeloma only), or
treatment-related AEs not returning to grade ≤ 1 (solid
tumors only) per Common Terminology Criteria for
Adverse Events (CTCAE), version 4.0. The MTD was
defined as the maximum dose, at which the probability
of a DLT was ≤25% in Part 1A and ≤ 33% in Parts 1B
and 1C. Treatment continued until disease progression,
intolerable toxicity, or withdrawal of consent.
Study assessments
Safety AEs were recorded for all enrolled patients.
Pharmacokinetics Plasma samples for the measurement of
AMG 232 pharmacokinetics in Parts 1 and 2 were col-
lected predose and at 1, 3, 5, and 7 h postdose on days
1 and 7 and 24 and 72 h postdose from day 7 of cycle
1; predose on days 1 and 7 of cycle 2; and at the end
of study. Plasma AMG 232 levels were measured using
a validated high performance liquid chromatography
mass spectrometry method [24]. Pharmacokinetic and
exposure parameters were estimated, including terminal
half-life (tmax), maximum observed plasma concentration
(Cmax), area under the concentration-versus-time curve
at 24 h (AUC24h), volume of distribution (Vz/F), termi-
nal elimination half-life (t1/2,z), and clearance (CL/F).
Non-compartmental analysis was performed using
WinNonlin Professional sof tware, vers ion 6.3.
Parameters were summarized descriptively.
Circulating MIC-1 In Parts 1 and 2, serum samples for the
assessment of circulat ing macrophage inhibitor
cytokine-1 (MIC-1) were collected on the pharmacoki-
netic sample schedule. Serum MIC-1 concentrations
were measured using a validated ELISA (human GDF-
15 Quantikine®, R&D Systems Inc.).
Efficacy Efficacy response was assessed using revised
Response Evaluation Criteria in Solid Tumors (RECIST),
version 1.1 [25] Macdonald criteria for GBM [26] or
International Myeloma Working Group (IMWG) response
criteria for multiple myeloma [27].
Statistical analysis
Primary endpoints were the patient incidence of AEs, DLTs,
and clinically significant changes in safety assessments; AMG
232 and pharmacokinetic parameters; and the MTD in Part 1.
Secondary/exploratory endpoints included tumor response
and change in serum MIC-1 level. Data were summarized
descriptively. Qualified researchers may request data from




Overall, 107 patients enrolled (dose escalation, n = 39;
dose expansion, n = 68). Patients in the dose escalation
had a variety of refractory advanced solid tumors, and
those in the dose expansion had WDLPS (n = 10),
DDLPS (n = 10), GBM (n = 10), other solid tumors
(n = 16), breast cancer (n = 12), or multiple myeloma
(n = 10; Table 1). Most patients had received 3 or more
lines of therapy (dose escalation, 69%; dose expansion,
72%).
AMG 232 was administered to all 39 patients in the
dose escalation (15 mg, n = 3; 30 mg, n = 3; 60 mg, n =
4; 120 mg, n = 7; 240 mg, n = 8; 300 mg, n = 4;
360 mg, n = 4; 480 mg, n = 6) and to all 68 patients
in the dose expansion (240 mg). The intermediate doses
of 300 mg and 360 mg were assessed due to the occur-
rence of AEs. Reasons for discontinuing treatment
across the entire study were disease progression (n =




Three patients in the dose escalation had DLTs. The
first patient (120-mg cohort) with esophageal cancer
had a DLT consisting of grade 3 thrombocytopenia on
day 15 that worsened to grade 4 on day 17, lasted
seven days, and required a platelet transfusion. The sec-
ond patient (360-mg cohort) with rectal cancer had a
DLT consisting of grade 4 thrombocytopenia on day
28. The third patient (480-mg cohort) with head and
neck cancer had grade 3 neutropenia on day 22 that
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delayed treatment in the next cycle and was therefore
considered a DLT. Two additional patients in the 300-
mg cohort had cytopenias (grade 4 neutropenia; grade 4
thrombocytopenia) outside of the 21-day DLT evaluation
window that were considered in the dose escalation de-
cisions. Based on the protocol-specified definition using
DLTs incidence, the MTD for AMG 232 for 7 days
Q3W was not reached. However, when the DLTs and
delayed cytopenias were considered, the highest safe
and tolerable dose of AMG 232 was 240 mg, which
was the dose evaluated in the dose expansion.
Safety and tolerability in the dose escalation
In the dose escalation, 37 (95%) patients had treatment-
emergent AEs (Table 2), most of which were grade 1 or
2. The most common (occurring in ≥20% of patients)
treatment-emergent AEs were diarrhea (67%), nausea
(59%), vomiting, (51%), fatigue (41%), decreased appe-
tite (39%), thrombocytopenia (36%), anemia (26%),
neutropenia (26%), and abdominal pain (21%). Thirty-
four (87%) patients in the dose escalation had AEs that
were considered by the investigators to be treatment
related. The most common (occurring in ≥20% of pa-
tients) treatment-related AEs were diarrhea (64%), nau-
sea (51%), vomiting (46%), fatigue (41%), thrombocy-
topenia (36%), decreased appetite (26%), and neutrope-
nia (21%). Most treatment-related AEs were grade 1 or
2.
Serious AEs occurred in 14 (36%) patients during the
dose escalation, including six (15%) whose serious AEs
were considered treatment-related and predominantly in-
cluded gastrointestinal toxicity (Table 2). Overall, eight
patients in the dose escalation had AEs resulting in
treatment discontinuation: thrombocytopenia (n = 5),
neutropenia (n = 2), and febrile neutropenia (n = 1).
Four patients in the dose escalation had fatal AEs of
disease progression while on study.
Safety and tolerability in the dose expansion
In the 240-mg dose expansion, 67 (99%) patients had
treatment-emergent AEs (Table 3), most of which were
grade 1 or 2. The most common (occurring in ≥20% of
patients) treatment-emergent AEs were diarrhea (72%),
nausea (72%), vomiting, (59%), fatigue (53%), de-
creased appetite (41%), anemia (25%), and thrombocy-
topenia (24%). Sixty-five (96%) patients in the dose
expansion had AEs that were considered by the investi-
gators to be related to treatment with AMG 232. The
most common (occurring in ≥20% of patients)
treatment-related AEs were diarrhea (68%), nausea
(68%), vomiting (47%), fatigue (47%), decreased appe-
ti te (41%), and thrombocytopenia (21%). Most
treatment-related AEs were grade 1 or 2.
During the dose expansion, 29 (43%) patients had
serious AEs, including seven (10%) whose serious
AEs were considered treatment-related (Table 3).
Overall, 13 (19%) patients in the dose expansion had
AEs resulting in treatment discontinuation: vomiting
(n = 4), fatigue (n = 2), and nausea, dyspnea, pulmonary






































































































ECOG, Eastern Cooperative Oncology Group
a Includes renal cell tumor (n = 2) and n = 1 each of mesothelioma, neu-
roendocrine cancer, rectal carcinoma, prostate cancer, neuroendocrine
carcinoid, cholangiocarcinoma, esophageal cancer, and granular cell
tumor
b Includes unknown (n = 2) and n = 1 each of bone tumor, cardia carcino-
ma, cholangiocarcinoma, endometrial cancer, ileal cancer, osteosarcoma,
prostate cancer, squamous lung cancer, and renal cell cancer
834 Invest New Drugs (2020) 38:831–843
embolism, asthenia, malaise, ECOG performance status
4, thrombocytopenia, neutropenia, intestinal adhesion ly-
sis, and oculogyric crisis (n = 1 each). Three patients in
the dose expansion had fatal AEs while on study, in-
cluding two with disease progression and one with
physical deterioration.
Pharmacokinetics of AMG 232
Plasma samples for the evaluation of AMG 232 phar-
macokinetics were available for 106 patients. AMG 232
pharmacokinetic profiles for the dose escalation
and dose expansion are shown in Fig. 1. Plasma
Table 2 Patient incidence of adverse events in the AMG 232 dose escalation



















Patients with any treatment-emergent
AE, n (%)
1 (33) 3 (100) 4 (100) 7 (100) 8 (100) 4 (100) 4 (100) 6 (100) 37 (95)
Patients with any treatment-emergent
serious AE, n (%)
1 (33) 0 0 3 (43) 4 (50) 2 (50) 0 4 (67) 14 (36)
Patients with any treatment-related AE,
n (%)
1 (33) 1 (33) 3 (75) 7 (100) 8 (100) 4 (100) 4 (100) 6 (100) 34 (87)
Grade 3 0 0 0 1 (14) 3 (38) 3 (75) 3 (75) 3 (50) 13 (33)
Grade 4 0 0 0 1 (14) 0 2 (50) 2 (50) 3 (50) 8 (21)
Grade 5 0 0 0 0 0 0 0 0 0
Treatment-related AEs occurring in ≥10% of patients, n (%)
Diarrhea 0 1 (33) 1 (25) 3 (43) 6 (75) 4 (100) 4 (100) 6 (100) 25 (64)
Nausea 0 1 (33) 3 (75) 3 (43) 5 (63) 1 (25) 4 (100) 3 (50) 20 (51)
Vomiting 0 1 (33) 0 2 (29) 5 (63) 3 (75) 3 (75) 4 (67) 18 (46)
Fatigue 1 (33) 1 (33) 1 (25) 3 (43) 4 (50) 2 (50) 0 4 (67) 16 (41)
Thrombocytopenia 0 0 0 1 (14) 1 (13) 3 (75) 4 (100) 5 (83) 14 (36)
Decrease appetite 0 0 1 (25) 2 (29) 2 (25) 1 (25) 3 (75) 1 (17) 10 (26)
Neutropenia 0 0 0 0 0 2 (50) 3 (75) 3 (50) 8 (21)
Anemia 0 0 0 0 1 (13) 0 2 (50) 2 (33) 5 (13)
Myalgia 0 0 0 1 (14) 0 0 2 (50) 1 (17) 4 (10)
Asthenia 0 0 0 0 1 (13) 1 (25) 2 (50) 0 4 (10)
Abdominal pain 0 0 0 0 2 (25) 1 (25) 1 (25) 0 4 (10)
Dysgeusia 0 0 0 0 2 (25) 1 (25) 1 (25) 0 4 (10)
Upper abdominal pain 0 0 0 1 (14) 1 (13) 1 (25) 1 (25) 0 4 (10)
Patients with any treatment-related
serious AE, n (%)
0 0 0 0 2 (25) 2 (50) 0 2 (33) 6 (15)
Vomiting 0 0 0 0 1 (13) 2 (50) 0 0 3 (8)
Grade 2 0 0 0 0 0 1 (25) 0 0 1 (3)
Grade 3 0 0 0 0 1 (13) 1 (25) 0 0 2 (5)
Diarrhea 0 0 0 0 1 (13) 1 (25) 0 0 2 (5)
Grade 2 0 0 0 0 1 (13) 0 0 0 1 (3)
Grade 3 0 0 0 0 0 1 (25) 0 0 1 (3)
Thrombocytopenia (grade 4) 0 0 0 0 0 0 0 2 (33) 2 (5)
Hematemesis (grade 3) 0 0 0 0 0 0 0 1 (17) 1 (3)
Neutropenia (grade 4) 0 0 0 0 0 0 0 1 (17) 1 (3)
Dehydration (grade 2) 0 0 0 0 0 1 (25) 0 0 1 (3)
Febrile neutropenia (grade 3) 0 0 0 0 0 1 (25) 0 0 1 (3)
Abdominal pain (grade 2) 0 0 0 0 1 (13) 0 0 0 1 (3)
Nausea (grade 3) 0 0 0 0 1 (13) 0 0 0 1 (3)
Non-cardiac chest pain (grade 3) 0 0 0 0 1 (13) 0 0 0 1 (3)
AE, adverse event
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concentrations of AMG 232 increased dose proportion-
ally. The mean AUC accumulation ratio between days 1
and day 7 across all dosing groups in the dose escala-
tion and in the dose expansion was less than 2-fold
with the once-daily dosing regimen (Table 4, Table 5).
The mean estimated apparent volume of distribution was
615 L across all dosing cohorts. With oral administra-
tion, the estimated mean apparent clearance of AMG
232 was 30.2 L/h across groups and varied among
individuals.
AMG 232 pharmacodynamic effects
Thirty-nine patients in the dose escalation had available
pre-treatment and post-treatment blood samples for the
assessment of serum MIC-1; serum MIC- was not
assessed in the dose expansion. From baseline to day
15, increases in serum MIC-1 (post-treatment to pre-
treatment ratios) were generally dose-dependent
(Fig. 2). Mean serum MIC-1 ratios increased up to
day 7 and decreased until cycle 2, suggesting that
MIC-1 changes were dependent on AMG 232 exposure.
Efficacy
Imaging for the local evaluation of tumor response was
available for 38 of 39 patients in the dose escalation
and 60 of 68 patients in the dose expansion. One pa-
tient in the dose escalation had no postbaseline imaging
due to an AE. Eight patients in the dose expansion had
no postbaseline imaging due to clinical disease progres-
sion (n = 3), AEs (n = 3), and patient request (n = 2). By
local evaluation, no objective responses were observed.
Per central evaluation, three patients (4%) with WDLPS,










Breast (n = 8)
ER + PR–







treatment-emergent AE, n (%)




5 (50) 4 (40) 7 (70) 5 (31) 3 (38) 1 (25) 4 (40) 29 (43)
Patients with any treatment-related
AE, n (%)
10 (100) 9 (90) 10 (100) 14 (88) 8 (100) 4 (100) 10 (100) 65 (96)
Grade 3 6 (60) 0 4 (40) 4 (25) 4 (50) 1 (25) 6 (60) 25 (37)
Grade 4 3 (30) 0 0 2 (13) 0 0 3 (30) 8 (12)
Grade 5 0 0 0 0 0 0 0 0
Treatment-related AEs occurring in ≥10% of patients, n (%)
Diarrhea 9 (90) 6 (60) 5 (50) 8 (50) 7 (88) 4 (100) 7 (70) 46 (68)
Nausea 10 (100) 8 (80) 4 (40) 11 (69) 6 (75) 3 (75) 4 (40) 46 (68)
Vomiting 7 (70) 2 (20) 3 (30) 8 (50) 6 (75) 2 (50) 4 (40) 32 (47)
Fatigue 8 (80) 7 (70) 6 (60) 6 (38) 3 (38) 0 2 (20) 32 (47)
Decrease appetite 7 (70) 4 (40) 1 (10) 4 (25) 5 (63) 3 (75) 4 (40) 28 (41)
Thrombocytopenia 6 (60) 1 (10) 2 (20) 2 (13) 0 0 3 (30) 14 (21)
Neutropenia 1 (60) 0 2 (20) 1 (6) 0 0 3 (30) 12 (18)
Anemia 5 (50) 0 0 3 (19) 0 1 (25) 1 (10) 10 (15)
Asthenia 0 1 (10) 0 2 (13) 1 (13) 1 (25) 4 (40) 9 (13)
Dysgeusia 1 (10) 1 (10) 1 (10) 2 (13) 2 (25) 0 2 (20) 9 (13)
Patients with any serious,
treatment-related AE, n (%)
2 (20) 0 1 (10) 0 2 (25) 0 2 (20) 7 (10)
Vomiting (grade 3) 0 0 0 0 1 (13) 0 2 (20) 3 (4)
Diarrhea (grade 3) 0 0 0 0 1 (13) 0 0 1 (2)
Nausea (grade 3) 0 0 0 0 1 (13) 0 0 1 (2)
Hyperamylasemia (grade 3) 0 0 1 (10) 0 0 0 0 1 (2)
Hyperlipasemia (grade 3) 0 0 1 (10) 0 0 0 0 1 (2)
Dehydration (grade 3) 1 (10) 0 0 0 0 0 0 1 (2)
Pulmonary embolism (grade 3) 1 (10) 0 0 0 0 0 0 1 (2)
AE, adverse event; DD, Dedifferentiated liposarcoma; WD, well differentiated liposarcoma
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squamous cell carcinoma, and breast cancer had uncon-
firmed partial responses with durations of 2.4, 0.1, and
2.0 months, respectively. In the dose escalation, 31
(80%) patients had stable disease and five (13%) had
progressive disease (Fig. 3a). Based on evaluation of
non-target lesions, 2 (5%) patients in the dose escalation
had non − complete response/non − progressive disease.
Overall, 45 (66%) patients in the dose expansion had
stable disease and 15 (22%) had progressive disease
(Fig. 3b). Stable disease as a best result in the dose
expansion was observed among 10 of 10 patients with
WDLPS, 7 of 10 with DDLPS, six of 10 with GBM, 10
Invest New Drugs (2020) 38:831–843 837
a
b
Fig. 1 Mean (± SD) pharmacokinetic profile of AMG 232 following oral administration every 3 weeks in the dose escalation (a) and in the dose
expansion (b). DDLPS, dedifferentiated liposarcoma; GBM, glioblastoma multiforme; OST, other solid tumor; WDLPS, well differentiated liposarcoma
Table 4 AMG 232 pharmacokinetic parameters in the dose escalation




























































Cmax, ng/mL 130 (64) 259 (211) 457 (277) 868 (816) 1560
(1460)



































CL/F, L/h 20.9 (15.1) 27.8 (33.7) 21.6 (15.2) 31.1 (19.6) 30.7 (19.5) 26.9 (25.0) 27.6 (17.4) 35.2 (25.6) 31.0 (20.6) 30.2
(20.4)
Vz/F, L 497 (336) 1110
(1660)
360 (19.9) 664 (324) 523 (404) 762 (584) 423 (386) 585 (308) 613 (452) 615 (500)
t1/2,z, h 16.7 (1.4) 19.2 (10.7) 14.3 (1.8) 12.4 (0.6) 12.4 (8.4) 13.3 (2.3) 9.5 (1.6) 13.7 (7.5) 14.0 (6.2) 14.0 (6.0)
AUC24h AR 1.10 (0.37) 1.38 (1.13) 1.76 (1.04) 2.63 (2.47) 2.10 (1.14) 2.42 (1.69) 1.29 (0.59) 0.95 (0.34) 1.49 (0.80) 1.58
(1.07)
AR, accumulation ratio (AUC24h cycle 1, day 1 / AUC24h cycle 1, day 7); AUC24h, area under the concentration-versus-time curve at 24 h; CL/F, clearance;
Cmax, maximum observed serum concentration; t1/2,z, terminal elimination half-life; tmax, time to reach Cmax; Vz/F, volume of distribution
a All data are mean (SD) except for tmax, which is median (range)




















Cmax, ng/mL 1350 (815) 986 (582) 978 (630) 1670 (858) 1920 (1010) 1360 (487) 1320 (687) 1390 (798)
tmax, h 3.1 (1.1–3.1) 2.0 (0.98–3.1) 3.0 (1.0–3.3) 3.0 (0.98–5.2) 2.8 (1.0–24) 2.1 (1.0–3.1) 2.0 (1.0–3.1) 3.0 (0.98–24)
AUC24h, ng•h/mL 9260 (5500) 8010 (6760) 5360 (3650) 10,800 (6270) 9660 (3890) 9430 (4480) 8220 (4790) 8830 (5400)
Day 7
Cmax, ng/mL 1230 (803) 1050 (660) 988 (591) 2200 (1400) 1350 (587) 1620 (923) 1190 (605) 1420 (961)
tmax, h 3.0 (1.0–5.1) 3.0 (1.0–3.1) 2.8 (1.0–5.0) 2.9 (0.92–5.0) 2.8 (1.1–5.1) 1.0 (1.0–3.0) 1.1 (1.0–3.4) 2.8 (0.92–5.1)
AUC24h, ng•h/mL 15,700 (13,800) 10,800 (9640) 9210 (6400) 17,200 (11,400) 10,400 (4380) 9960 (7830) 8450 (3560) 12,300 (9550)
CL/F, L/h 30.6 (24.1) 39.5 (29.0) 41.2 (27.5) 18.5 (9.1) 27.6 (12.6) 36.4 (22.8) 33.6 (15.4) 31.1 (20.9)
Vz/F, L 389 (237) 537 (435) 1010 (671) 353 (360) 689 (529) 814 (455) 859 (277) 627 (461)
t1/2,z, h 11.2 (4.3) 10.9 (4.3) 18.5 (5.3) 14.1 (7.6) 15.0 (6.3) 17.4 (6.9) 15.4 (3.5) 14.3 (5.8)
AUC24h AR 1.62 (0.95) 1.43 (0.72) 1.50 (0.31) 1.52 (0.57) 1.01 (0.25) 0.99 (0.43) 1.39 (1.05) 1.40 (0.72)
AR, accumulation ratio (AUC24h cycle 1, day 1 / AUC24h cycle 1, day 7); AUC24h, area under the concentration-versus-time curve at 24 h; CL/F, clearance;
Cmax, maximum observed serum concentration; t1/2,z, terminal elimination half-life; tmax, time to reach Cmax; Vz/F, volume of distribution
a All data are mean (SD) except for tmax, which is median (range)
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of 16 with other solid tumors, 10 of 12 with breast
cancer, and 5 of 10 with multiple myeloma.
Duration of stable disease in the dose escalation and
across histologies in the dose expansion is summarized
in Fig. 4. The median duration of stable disease in the
dose escalation was 3.1 months (range, 0.7–22.4 mo). In
the dose expansion, the overall median duration of sta-
ble disease was 2.0 months (range, 0.5–12.9) overall,
3.9 months (range 1.9–6.1) among patients with
WDLPS, 2.0 months (0.9–6.9) among patients with
DDLPS, 1.8 months (0.5–11.9) among patients with
GBM, 3.3 months (0.9–12.9) among patients with other
solid tumors, 2.0 months (0.9–4.0) among patients with
ER + PR+ breast cancer, and 1.4 months (0.9–3.8)
among those with ER + PR– breast cancer.
Discussion
In this first-in-human study, AMG 232 was generally
well tolerated up to 240 mg. AMG 232 doses up to
480 mg QD for seven days in a 21-day cycle were
assessed; however, the MTD was not reached. Three
patients had DLTs, two with thrombocytopenia and one
with neutropenia. Based on these DLTs and other cyto-
penias outside of the DLT evaluation window, AMG
232 240 mg was selected as the highest safe and toler-
able dose for evaluation in the dose expansion. In both
phases of the study, AMG 232–related AEs were gen-
erally mild to moderate, with the most frequently occur-
ring AEs being diarrhea, nausea, vomiting, fatigue, de-
creased appetite, and anemia. Among the AEs resulting
in treatment discontinuation, thrombocytopenia, neutro-
penia, and gastrointestinal toxicity were the most fre-
quent. These results are consistent with other clinical
studies of MDM2 inhibitors, in which myelosuppression
and gastrointestinal toxicity have been reported [18, 19,
28–33]. In this study, five patients died due to disease
progression while on the study.
Following QD treatment for seven days in a 21-
day cycle, AMG 232 plasma concentrations increased
generally dose proportionally, and across all patients,
the mean AUC accumulation ratio between days 1 and
7 was less than 2-fold. Overall, AMG 232 exhibited an
acceptable pharmacokinetic profile in this population.
Furthermore, dose-dependent increases in serum MIC-1
levels from baseline to day 15 of treatment indicated
p53 pathway activation, consistent with previous studies
of MDM2 inhibitors [19–21].
One of the objectives of the dose expansion was to
assess the antitumor activity of AMG 232 among pa-
tients not only with P53WT tumors but also among
those with MDM2 amplification and MDM2 overexpres-
sion, which is common in liposarcomas, GBM, breast
cancer, and multiple myeloma [5–11] Per local evalua-
tion, no objective response were observed. Per central
evaluation, 3 patients had partial responses. Overall, sta-
ble disease was observed in 45 of 68 (66%) patients in
the dose expansion, including all 10 patients with
WDLPS, 7 of 10 with DDLPS, 6 of 10 with GBM,
10 of 16 with other solid tumors, 7 of 12 with breast
cancer, and 5 of 10 with multiple myeloma. Stable dis-
ease was observed among patients with WDLPS (medi-
an, 3.9 months; range, 1.9–6.1), which is naturally an
indolent disease, followed by other solid tumors (medi-
an, 3.3 months; range, 1.9–12.9), DDLPS (median,
2.0 months; range, 1.8–.6.9), GBM (median, 1.8 months;
range, 1.4–11.9), breast cancer (median, 2.0 months;
range, 1.7–4.0), and multiple myeloma (median,
1.0 months; range, 1.2–2.0). Our results are consistent
with those of previous reports demonstrating limited
clinical activity with HDM2/MDM2 inhibitors [18, 20,
31, 34–36]. Because the development of TP53 muta-
tions may contribute to the development of resistance
to treatment with HDM2/MDM2 inhibitors, investigation
of HDM2/MDM2 inhibitors in combination with other
agents may be appropriate [34].
In conclusion, AMG 232 showed acceptable safety, dose-
proportional pharmacokinetics, and on-target activity as
Fig. 2 Mean (± SE) ratio of post-
treatment versus pre-treatment
serum MIC-1 in the dose
escalation
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monotherapy administered at oral doses up to 240 mg QD on
days 1–7 per 3-week cycle in patients with P53WT solid
tumors. No responses were observed per local evaluation but
3 patients had unconfirmed partial responses per central
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a
b
Fig. 3 Best change from baseline in the sum of longest diameters of target
lesions in the dose escalation (a) and in the dose expansion (b). ACC,
adenoid cystic carcinoma; CAC, cholangiocarcinoma; Chondro,
chondrosarcoma; DDLPS, dedifferentiated liposarcoma; Esoph,
esophageal; GBM, glioblastoma multiforme; GPL, glandular parotis
left; Gran, granular cell tumor; Leio, leiomyosarcoma; Mel, melanoma;
Neuro, neuroendocrine; NSCLC, non–small-cell lung cancer; OST, other
solid tumor; Panc, pancreatic; Pleural, pleural mesothelioma; Saliv,
salivary gland; SCCHN, squamous cell carcinoma of the head and
neck; SFT, solitary fibrous tumor; STS, soft tissue sarcoma; WDLPS,
well differentiated liposarcoma. *Patient had partial response per central
review
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a
b
Fig. 4 Duration of stable disease in the dose escalation (a) and in the dose expansion (b). DDLPS, dedifferentiated liposarcoma; GBM, glioblastoma
multiforme; OST, other solid tumor; WDLPS, well differentiated liposarcoma
evaluation. Stable disease was observed among patients re-
gardless of MDM2 amplification or overexpression. Future
evaluation of AMG 232 in hematologic malignancies and sol-
id tumors should be considered.
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